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For 20 years we and others have been attempting to harness the power of transgenic 
livestock technology to enhance agricultural productivity.  We came to believe the true power of 
transgenesis lies not in advancing the rate of genetic selection, but rather in endowing animals 
with traits that could not be achieved by standard breeding strategies.  Many animal scientists 
started dreaming about altering the composition of milk to produce new dairy products. Ideas of 
transgenic cows producing low-fat milk, low-lactose milk and milk for the production of 
spreadable butter quickly captured the research community. That is, until the processors pointed 
out that they can already produce those products with cost efficiencies difficult to match by 
genetic engineers.   
Biotechnology companies recognized the potential for producing bioactive compounds in 
the mammary glands of farm animals.  There have been numerous examples of cost effective 
production of pharmaceuticals in milk of livestock.  But, post harvest hurdles have limited 
product development.  Nevertheless, several companies have mammary gland derived 
pharmaceuticals in the final stages of product development.  The first nutraceutical produced in 
the milk of genetically engineered cattle to hit the market is likely to be lactoferrin.  The 
academic community too has been exploring the potential of manipulating milk proteins to 
enhance milk’s healthfulness, and nutritional and manufacturing properties.  Instead, we have 
chosen to address mammary gland disease.       
Our efforts have been focused on developing mastitis resistant dairy cattle for a variety of 
reasons.  Mastitis is a disease of the mammary gland caused by pathogens that find their way into 
the lumen of the gland through the teat canal.  Firstly, mastitis is a significant detriment to 
agricultural productivity worthy of the significant investment in resources needed to develop a 
transgenic cattle project. Mastitis is on every dairy farm and affects both the production and post 
harvest segments of the dairy industry.  Estimated losses due to mastitis approach $2 billion 
annually in the United States alone, but it is clearly a global disease. Secondly, the incidence of 
mastitis has not declined appreciably since the implementation of the five-point control plan two 
decades ago. This plan, which includes extensive antibiotic therapy and culling of infected 
animals, did have a major beneficial effect, and some pathogens, such as Streptococcus 
agalactiae have been virtually eliminated in some countries. However, producers are still 
expending considerable effort in battling environmental pathogens such as Escherichia coli and 
Streptococcus uberis, and the contagious, often subclinical Staphlococcus aureus.  Furthermore, 
because of the low heritability of mastitis resistance selective breeding has not been a useful tool 
for combating mastitis. Additionally, there is a strong desire to reduce the on-farm use of those 
antibiotics that are also used in human medicine, and certainly not least is a desire to improve the 
welfare of our dairy animals.  
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Staphylococcus aureus is one of the most prevalent bacteria that cause mastitis and is 
responsible for ~25-30% of all intramammary infections.  Mastitis caused by Staphylococcus 
aureus is most often subclinical, however, a substantial incidence rate of clinical mastitis is 
associated with this pathogen.  Staphylococcus aureus is regarded as a contagious mastitis 
pathogen because it is commonly spread from infected to non-infected cows at milking.  
Although the main reservoir of these bacteria is infected udders, Staphylococcus aureus have 
been recovered from surfaces all over the cow and can be readily disseminated from animal 
handlers who are carriers of this pathogen.  Following penetration of the teat canal, these bacteria 
release a variety of toxins and products that are injurious to the milk producing cells of the 
mammary gland and impair the gland's immune defense mechanisms.  The intramammary 
formation of abscesses around these bacteria and their capacity to reside intracellularly 
contribute to the ability of Staphylococcus aureus to establish a chronic infection that can persist 
for the life of the animal.  The result of establishment of a subclinical, chronic intramammary 
infection is long-term decreased milk production that often goes undetected.  
  Effective strategies for the prevention and treatment of mastitis caused by Staphylococcus 
aureus remain elusive.  Vaccines to prevent the establishment of intramammary infection by this 
pathogen have been around for decades, however, their efficacy has been limited.  Their limited 
effectiveness may be due, in part, to improper immunization schedules, ineffective adjuvant 
formulation, and their inability to cross-protect against various strains.  Since multiple strains can 
be present within any one herd or even within an individual cow, vaccines or other strategies 
with less restrictive strain specificity will be required to decrease the incidence of mastitis caused 
by Staphylococcus aureus.  
Once established, Staphylococcus aureus infections are difficult to treat.  These bacteria 
are able to reside intracellularly and are shed periodically into the milk.  Their residence inside of 
the cells within the gland and the formation of abscesses around foci of infection restrict their 
contact with administered antibiotics.  The percentage of Staphylococcus aureus-infected 
animals that can be cured during lactation with currently approved antibiotics is only between 
10-30%.  In a recent study of the efficacy of pirlymycin, a common antibiotic used in the 
treatment of these infections, only 13% of Staphylococcus aureus intramammary infections were 
cured following the recommended 2 day therapy.  Extending the therapy to 5 consecutive days 
increased the cure rate to only 31%, a level which is below the break-even point at which costs 
incurred through treatment are balanced by increased production and the premium pay associated 
with milk containing lower numbers of milk somatic cells.  Thus, treatment options for lactating 
cows infected with Staphylococcus aureus remain suboptimal. 
Lysostaphin is a proteolytic enzyme produced by Staphylococcus simulans that cleaves 
specific bonds found in the peptidoglycan cell wall component of Staphylococcus aureus.  Due 
to its potent lytic activity towards this pathogen, lysostaphin's ability to kill Staphylococcus 
aureus has been evaluated in several animal disease models .  In a model of endocarditis in 
rabbits, lysostaphin was shown to be more effective than vancomycin at reducing valve 
vegetation bacterial counts.  Further, lysostaphin has been reported to be effective in the 
treatment of eye infections caused by Staphylococcus aureus.  With the advent of antibiotic-
resistant bacteria, another key finding of lysostaphin's ability to kill Staphylococcus aureus is its 
equivalent lytic activity toward both methicillin-resistant and sensitive strains. 
The efficacy of lysostaphin for the treatment of Staphylococcus aureus-induced mastitis 
has also been evaluated in a variety of animal models, including mice, goats, and cows.  Infusion 
of lysostaphin into the Staphylococcus aureus-infected glands of mice was shown to significantly   3
reduce the number of viable bacteria.  Lysostaphin has also been demonstrated to have a cure 
rate of ~20% when used to treat Staphylococcus aureus intramammary infections in lactating 
cows.  Although this rate is comparable to commonly used antibiotics, lysostaphin's targeted 
specificity and low toxicity may make its use more advantageous.  Further studies evaluating 
formulation, dosing, and treatment durations will be needed to determine whether its efficacy, 
when used as an intramammary infusate, can be enhanced.   
In a recently published study  we describe transgenic cattle, carrying a mammary-specific 
transgene encoding lysostaphin, that are resistant to infection by Staphlococcus aureus.  Our first 
three lactating transgenic cows were infused with Staphlococcus aureus multiple times during 
their first lactations.  Milk levels of lysostaphin varied between the transgenic animals and 
ranged from 0.9 to 14 µg/ml.  Of the mammary glands of three transgenic cows that were infused 
with Staphylococcus aureus, only 14% became infected.  In comparison, 71% of the quarters 
challenged in the control animals became infected.  Even the transgenic cow expressing the least 
amount of lysostaphin (i.e., 0.9 µg/ml) had an infection rate of only 33%.  Of the three transgenic 
cows infused with Staphylococcus aureus, who expressed the highest concentration of 
lysostaphin in her milk (i.e., 11 µg/ml), was completely resistant to infection.  The level 
lysostaphin in milk of the three transgenic cows remained fairly consistent throughout lactation.  
The consistent level of expression conferred resistance throughout lactation.  
  We monitored cows for both a febrile response and for the induction of acute phase 
protein synthesis, the latter of which is a sensitive marker of infection.  In addition to these 
systemic indicators, individual quarters were monitored for changes in milk somatic cell counts, 
which during mastitis are primarily composed of white blood cells that play a role in combating 
infection.  As expected, control cows that developed established Staphylococcus aureus 
infections had increased body temperatures, elevated levels of circulating acute phase proteins, 
and increased milk somatic cells counts.  In contrast, the transgenic animals demonstrated none 
of these signs of inflammation.  These data suggest that lysostaphin prevents infection through 
its bactericidal properties and, thus, prevents the onset of inflammation. 
We concluded from that limited study that the degree of protection afforded by the 
transgene was related to the concentration of lysostaphin in milk, as might be expected.  We 
recently verified an animal from a fourth line, with an intermediate level of lysostaphin 
expression, is also protected against Staphlococcus aureus infection.  In vitro, bacteria lysis 
assays confirmed milk from all of the animals kill Staphlococcus aureus in a dose dependent 
manner.   But the lytic activity of the milk is less than would be predicted from lysostaphin 
concentration determined by ELISA.    
The diminished specific activity of lysostaphin was not a total surprise.  We observed the 
same phenomena in transgenic mice carrying a similar transgene.  Cell culture experiments 
conducted prior to the mouse experiments revealed that native lysostaphin was being 
glycosylated, and completely inactivated by mammalian cells. Thus, we modified the 
glycosylation motifs within the lysostaphin coding sequence, to allow for production of bioactive 
lysostaphin. In doing so we may have inadvertently altered the protein’s lytic potency.  This 
modification appears to have the same consequence in cattle as in mice.   
On the other hand, our transgenic mice were not a good predictor of transgene expression 
levels in cows.  We may have influenced the level of expression by addition of enhancements to 
the transgene necessitated by our need for selectable markers to facilitate the somatic cell nuclear 
transfer process.  A neomycin resistance gene, driven by a SV40 promoter was used to select for 
stable fibroblast integrants, while a second gene, a green fluorescent protein, driven by the   4
human elongation factor regulatory element, was used to confirm that cloned blastocysts 
expressed a functional transgene product before embryo transfer.   
The benefits derived from these selectable markers may be counter balanced by their 
possible negative consequences.  It is possible they are responsible for the relatively 
unimpressive levels of transgene expression observed in the cows.  Both the neomycin resistance 
gene and the GFP gene are littered with CpG islands (stretches of 500 bases with 60% or greater 
CG content, and with CG dinucleotide content 65% greater than normally observed in the 
genome).  Such sequences are well known for their propensity to become methylated and down 
regulate transgene expression.   
The lysostaphin transgene clearly affords protection against Staphlococcus aureus 
mastitis. However, these animals have no special protection against other mastitis causing 
pathogens.  To deal with other pathogens we are searching for additional antimicrobials based on 
an ever growing list of criteria. Clearly candidate genes must target an economically important 
pathogen, and cause no harm to the animal or the milk consumer. The protein must have 
antimicrobial activity in milk, a criterion that may eliminate a number of potential candidates, 
and, the new antimicrobial should not alter milk’s physical, chemical or nutritional properties. 
Ideally the protein should be effective at low concentrations to avoid major changes in the milk 
protein profile.  Finally, since cheese and yogurt production relies on bacterial cultures, the 
antimicrobial should not survive pasteurization, and if it does, should not inhibit growth of 
common starter culture organisms, or interfere with processing.  Furthermore, it should be noted 
that this general strategy is based on the assumption that antimicrobial peptides will have no 
biological activity when taken orally.  An assumption that has significant precedence, but of 
course, needs to be tested.   
Creating mastitis resistant cows is obviously of value to the dairy industry.  It still 
remains to be determined if this approach negatively impacts the downstream use and processing 
of milk as a food stuff.  However, our recent publication leaves little doubt that a transgene can 
offer disease protection.  Once the efficacy of this technology is proven, it is easy to imagine 
transgenic milk that not only protects against mastitis, but which contains agents that inhibit the 
growth of other unwanted microbes, effectively extending shelf life of milk and milk products.  
The scientific hurdles involved in finding a series of antimicrobials that meet the criterion 
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What has been done ? 
Transgenic Livestock goalsThe Mastitis Project
Goal: Reduce incidence and susceptibility to mastitis in cattle.
Facts about mastitis
• A third of dairy cows in the U.S. become infected
• Mastitis costs US producers  ≈ $2 Billion / year
 Treatment costs
 Reduced milk yield, shelf-life, cheese yield
 Animal well-being diminished, premature culling
• Vaccines, antibiotics and selective breeding are minimally effectiveThe Mastitis Project
Goal: Reduce incidence and susceptibility to mastitis in cattle.
Facts about mastitis
• Disease is on every dairy farm
• Staphylococcus aureus accounts for about a third of cases
Staph. aureus
Culling is often the only solutionThe Mastitis Project
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First genetically modified cows 





















































Estimated adult performance (305 Mature Equivalents) of 
Transgenic clones and their “Mother”












Milk Protein from Transgenic and Non-tg Jerseys
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Lysis of S. aureus by Milk from Transgenic Cows
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3 S. aureus strains: 
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3 S. aureus strains: 
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Saline in the 4thNeutrophils
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S. aureus Milk somatic cell response
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S. aureus Milk somatic cell response
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S. aureus Milk somatic cell response
Saline treated glands
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Time Post Infusion (h)








































Local responseInfection rate ( Infection = 2 consecutive milk samples with live S. aureus)
1 (17%) 6 Transgenic 204   (0.6)
2 (33%) 6 Transgenic 001   (0.7)
0 9 Transgenic 101   (12)
30 (63%) 48 10 Non-TG
1 (4%) 23 Saline infused glands
Glands Cows




No. No. Genotype• Immediate: Is the lysostaphin milk OK ?
• Identify additional anti-mastitis peptides
• Can we avoid resistant strains ?
Future plans
• Lysostaphin can protect against 
infection (3 µg/ml is probably enough)
• Lysostaphin seems to cause no harm
SummaryJust the Beginning     